Multizentrische Studie
Avacopan for ANCA-associated vasculitis: Beyond the 52-week treatment course
Clinical Nephrology · 2025
DOI: 10.5414/cn111775 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Ella Eisinger und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisHumansMaleRetrospective StudiesMiddle AgedFemaleGlomerular Filtration RateAgedAdultTime FactorsTreatment OutcomeRemission Induction
Zitieren
APA
Eisinger, E., Geara, A. S., Chang, B., Reddivari, P., Ford, J., Gewurz-Singer, O., & Geetha, D. (2025). Avacopan for ANCA-associated vasculitis: Beyond the 52-week treatment course. Clinical Nephrology. https://doi.org/10.5414/cn111775
Vancouver
Eisinger E, Geara AS, Chang B, Reddivari P, Ford J, Gewurz-Singer O, et al. Avacopan for ANCA-associated vasculitis: Beyond the 52-week treatment course. Clinical Nephrology. 2025. doi:10.5414/cn111775
BibTeX
@article{Eisinger2025,
author = {Eisinger, Ella and Geara, Abdallah S and Chang, Bryan and Reddivari, Preethi and Ford, Julia and Gewurz-Singer, Ora and Geetha, Duvuru},
title = {Avacopan for ANCA-associated vasculitis: Beyond the 52-week treatment course},
journal = {Clinical Nephrology},
year = {2025},
doi = {10.5414/cn111775}
}
EUVIMED